Statins and other drugs are widely used to lower the LDL-cholesterol level, which has been shown to prevent cardiovascular events. In this Review, Dadu and Ballantyne review the latest evidence on a novel class of LDL-lowering agents: proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. In particular, monoclonal antibodies against PCSK9 have proven efficacious and safe in phase I–III clinical trials.
- Razvan T. Dadu
- Christie M. Ballantyne